AU2012391162A1 - Novel MVA virus and uses thereof - Google Patents
Novel MVA virus and uses thereof Download PDFInfo
- Publication number
- AU2012391162A1 AU2012391162A1 AU2012391162A AU2012391162A AU2012391162A1 AU 2012391162 A1 AU2012391162 A1 AU 2012391162A1 AU 2012391162 A AU2012391162 A AU 2012391162A AU 2012391162 A AU2012391162 A AU 2012391162A AU 2012391162 A1 AU2012391162 A1 AU 2012391162A1
- Authority
- AU
- Australia
- Prior art keywords
- amino acid
- gene product
- virus
- cell
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24064—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/069256 WO2014048500A1 (en) | 2012-09-28 | 2012-09-28 | Novel mva virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2012391162A1 true AU2012391162A1 (en) | 2015-04-09 |
Family
ID=46982581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012391162A Abandoned AU2012391162A1 (en) | 2012-09-28 | 2012-09-28 | Novel MVA virus and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9732325B2 (enExample) |
| EP (1) | EP2900810B1 (enExample) |
| JP (1) | JP2015535687A (enExample) |
| CN (1) | CN104812894B (enExample) |
| AU (1) | AU2012391162A1 (enExample) |
| BR (1) | BR112015006798A2 (enExample) |
| CA (1) | CA2885240A1 (enExample) |
| DK (1) | DK2900810T3 (enExample) |
| IN (1) | IN2015DN02335A (enExample) |
| MX (1) | MX2015003687A (enExample) |
| RU (1) | RU2015115898A (enExample) |
| WO (1) | WO2014048500A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11104884B2 (en) | 2017-02-23 | 2021-08-31 | Probiogen Ab | Vaccinia virus vectors related to MVA with extensive genomic symmetries |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| CN108371715A (zh) * | 2018-01-03 | 2018-08-07 | 肖小林 | 一种病毒的靶向性防治药物 |
| JP2021535730A (ja) * | 2018-05-11 | 2021-12-23 | シティ・オブ・ホープCity of Hope | 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用 |
| CN112384615A (zh) | 2018-07-04 | 2021-02-19 | 普罗拜奥根股份公司 | 用于纯化包膜病毒的方法 |
| WO2022109133A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| WO2023128672A1 (ko) * | 2021-12-29 | 2023-07-06 | 재단법인 아산사회복지재단 | 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주 |
| WO2023223183A1 (en) | 2022-05-16 | 2023-11-23 | Crispr Therapeutics Ag | Picornaviral vectors for gene editing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| WO2005048957A2 (en) | 2003-02-20 | 2005-06-02 | Therion Biologics Corporation | Novel insertion sites in pox vectors |
-
2012
- 2012-09-28 US US14/431,814 patent/US9732325B2/en active Active
- 2012-09-28 JP JP2015533460A patent/JP2015535687A/ja active Pending
- 2012-09-28 WO PCT/EP2012/069256 patent/WO2014048500A1/en not_active Ceased
- 2012-09-28 EP EP12769398.4A patent/EP2900810B1/en active Active
- 2012-09-28 MX MX2015003687A patent/MX2015003687A/es unknown
- 2012-09-28 CA CA2885240A patent/CA2885240A1/en not_active Abandoned
- 2012-09-28 CN CN201280077370.4A patent/CN104812894B/zh active Active
- 2012-09-28 DK DK12769398.4T patent/DK2900810T3/en active
- 2012-09-28 BR BR112015006798A patent/BR112015006798A2/pt not_active IP Right Cessation
- 2012-09-28 IN IN2335DEN2015 patent/IN2015DN02335A/en unknown
- 2012-09-28 AU AU2012391162A patent/AU2012391162A1/en not_active Abandoned
- 2012-09-28 RU RU2015115898A patent/RU2015115898A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK2900810T3 (en) | 2019-04-29 |
| IN2015DN02335A (enExample) | 2015-08-28 |
| CN104812894A (zh) | 2015-07-29 |
| WO2014048500A1 (en) | 2014-04-03 |
| US9732325B2 (en) | 2017-08-15 |
| CA2885240A1 (en) | 2014-04-03 |
| MX2015003687A (es) | 2015-06-15 |
| JP2015535687A (ja) | 2015-12-17 |
| BR112015006798A2 (pt) | 2017-11-21 |
| RU2015115898A (ru) | 2016-11-20 |
| EP2900810A1 (en) | 2015-08-05 |
| EP2900810B1 (en) | 2019-02-20 |
| CN104812894B (zh) | 2021-10-22 |
| US20150299666A1 (en) | 2015-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9732325B2 (en) | MVA virus and uses thereof | |
| TW575664B (en) | Recombinant MVA virus, and the use thereof | |
| JP5783642B2 (ja) | Ｍｖａの主なゲノム欠失を含むワクシニアウイルス変異体 | |
| KR20130030298A (ko) | 불멸화 조류 세포주들 | |
| BRPI0215003B1 (pt) | método para a recuperação e purificação de poxvírus a partir de células infectadas | |
| Jordan et al. | A chemically defined production process for highly attenuated poxviruses | |
| Léon et al. | The EB66® cell line as a valuable cell substrate for MVA-based vaccines production | |
| US11999975B2 (en) | Method for purifying an enveloped virus | |
| US11104884B2 (en) | Vaccinia virus vectors related to MVA with extensive genomic symmetries | |
| Melamed et al. | Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants | |
| WO2004087047A2 (en) | Mutants of replication competent vaccinia virus | |
| AU2009201629A1 (en) | Production of ALVAC on avian embryonic stem cells | |
| Tscherne et al. | Generating MVA-Vector Vaccine Candidates and Testing Them in Animal Models | |
| KR20250156704A (ko) | 메추라기 세포 배양을 통한 폭스바이러스 생산 | |
| WO2024188801A1 (en) | Use of quail cell lines for poxvirus production | |
| WO2024245722A2 (en) | Rapid selection system for the generation of recombinant enveloped viruses | |
| AU2024280931A9 (en) | Rapid selection system for the generation of recombinant enveloped viruses | |
| MX2013001772A (es) | Linea celular de amniocitos humanos permanente para la produccion de virus de influenza. | |
| EP2199385A1 (en) | Specific and persistent activation of heat shock response in cell lines using a viral factor | |
| Ricci | Generation of modified vaccinia virus ankara recombinants by rescue of the essential D4R gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |